Shots:

• Intellia to receive $10M upfront- milestones and royalties on sales. Novartis to get rights to Intellia’s CRISPR/Cas9 technology for the development of ex-vivo cell therapy using ocular stem cells
• Under the extension of previous agreement with Novartis- Intellia to get the rights of Novartis’ lipid nanoparticle (LNP) technology for development of genome editing in ex-vivo & in-vivo
• Intellia’s CRISPR/Cas9 technology enables editing of disease-associated genes- providing improved cell therapies for cancer and immunological diseases

Ref : Intellia Therapeutics | Image: Greek Reporter